Key result
Patients with coronary heart disease had significantly higher plasma 14,15-DHET levels (2.53 ng/mL) compared to healthy controls (1.65 ng/mL, P=0.036), which positively correlated with hs-CRP levels.
Why the study?
Are plasma 14,15-DHET levels elevated in patients with coronary heart disease and do they correlate with inflammation and lipoproteins?
Cross-Sectional (n=120)
No
Are plasma 14,15-DHET levels elevated in patients with coronary heart disease and do they correlate with inflammation and lipoproteins?
Absolute Event Rate: 2.53% vs 1.65%
p-value: p=0.036
Elevated plasma 14,15-DHET levels in patients with coronary heart disease correlate with hs-CRP, suggesting that decreased 14,15-EET levels may be involved in the inflammatory process of atherosclerosis.
May mark inflammation in CHD; hypothesis-generating for EET pathway role and needs prospective validation.
BACKGROUND: 14,15-Epoxyeicosatrienoic acids (14,15-EETs) generated from arachidonic acid by cytochrome P450 epoxygenases have beneficial effects in certain cardiovascular diseases, and increased 14,15-EET levels protect the cardiovascular system. 14,15-EETs are rapidly hydrolyzed by soluble epoxide hydrolase (sEH) to the corresponding 14,15-dihydroxyeicosatrienoic acids (14,15-DHETs), which are generally less biologically active but more stable metabolite. A functionally relevant polymorphism of the CYP2J2 gene is independently associated with an increased risk of coronary heart disease (CHD), and the major CYP2J2 product is 14,15-EETs. 14,15-DHETs can be considered a relevant marker of CYP2J2 activity. Therefore, the aim of the present study was to evaluate the plasma 14,15-DHET levels to reflect the 14,15-EET levels in an indirectly way in patients with CHD, and to highlight the growing body of evidence that 14,15-EETs also play a role in anti-inflammatory and lipid-regulating effects in patients with CHD. This was achieved by investigating the relationship between 14,15-DHETs and high-sensitivity C-reactive protein (hs-CRP) and blood lipoproteins. METHODS: Samples of peripheral venous blood were drawn from 60 patients with CHD and 60 healthy controls. A 14,15-DHET enzyme-linked immunosorbent assay kit (14,15-DHET ELISA kit) was used to measure the plasma 14,15-DHET levels. Hs-CRP, total cholesterol, triglyceride, high-density lipoprotein cholesterol, and low-density lipoprotein-cholesterol levels were measured. RESULTS: 14,15-DHET levels (2.53 ± 1.60 ng/mL) were significantly higher in patients with CHD as compared with those of the healthy controls (1.65 ± 1.54 ng/mL, P < 0.05). There was a significant positive correlation between 14,15-DHETs and hs-CRP levels (R = 0.286, P = 0.027). However, there was no significant correlation between 14,15-DHETs and blood lipoproteins (all, P > 0.05). CONCLUSIONS: Increased plasma 14,15-DHET levels reflect the decreased of 14,15-EET levels in an indirectly way. Indicated that decreased plasma 14,15-EET levels might be involved in the inflammatory reaction process in atherosclerosis.
No takes yet. Share an insight, caveat, or question.
Tian et al. (2013) conducted a cross-sectional in Coronary heart disease (n=120). Coronary heart disease vs. Healthy controls was evaluated on Plasma 14,15-DHET levels (p=0.036). Patients with coronary heart disease had significantly higher plasma 14,15-DHET levels (2.53 ng/mL) compared to healthy controls (1.65 ng/mL, P=0.036), which positively correlated with hs-CRP levels.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: